跳至主要内容
临床试验/NCT02882581
NCT02882581已完成1 期

Metformin in Breast Cancer, Visualized With Positron Emission Tomography

Aarhus University Hospital4 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2016年8月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
7
试验地点
4
主要终点
Metformin uptake in breast cancer

研究概览

简要总结

The general purpose of the trial is to investigate whether metformin is taken up into the breast tumor. Studies in the last few years have shown an effect of metformin on cell proliferation on breast cancer. It is though unclear whether the effect on tumor is direct, indirect or a combination of the two. The investigators plan to:

  • investigate if metformin is taken up in breast cancer using our novel 11C-metformin tracer and positron emission tomography (PET)
  • investigate whether the uptake is correlated to the amounts of organic cation transporters (OCT1-3, MATE 1 &2 and PMAT) using quantitive polymerase chain reaction (qPCR).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • over 50 years
  • C. mammae
  • Tumor size: > 10 mm in diameter
  • Unilateral cancer
  • WHO performance status 0-1

排除标准

  • Severe heart- or kidney failure
  • Pregnant or breast feeding
  • If the patient is found not eligible for participation in the study på principal investigator

研究组 & 干预措施

11C-metformin

Experimental

All participants allocated to the study will be included in this arm

干预措施: 11C-metformin (Radiation)

结局指标

主要结局

Metformin uptake in breast cancer

时间窗: 12 months

次要结局

未报告次要终点

研究者

发起方
Aarhus University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Elias Immanuel Ordell Sundelin

MD

Aarhus University Hospital

研究点 (4)

Loading locations...

相似试验